Top 4 Health Care Stocks That Are Preparing To Pump This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The…
French Drugmaker Sanofi Agrees To Buy Inhibrx’s Candidate For Rare Genetic Indication, For About $2.2B
Sanofi's strategic acquisition of Inhibrx's INBRX-101, a alpha-1 antitrypsin therapy in a registrational trial. Learn about the $2.2B merger details and Inhibrx Biosciences' spin-off. Closing expected in Q2 2024.
Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx Project
Following the acquisition, New Inhibrx will continue to operate under the "Inhibrx" name, with Mark Lappe as Chairman and CEO.
Inhibrx Sells INBRX-101 To Sanofi For Up To $2.2B, Spins Off New Company With All Non-101 Assets And Liabilities
Inhibrx, Inc. shareholders will receive per share consideration of $30 per share in cash, a CVR equal to $5, plus 0.25 shares in New Inhibrx, a new publicly traded company that retains all non-101 assets
Watching Axos Financial; The Bear Cave Newsletter Issues Report On Co Titled “Problems At Axos Financial (AX)”
https://thebearcave.substack.com/p/problems-at-axos-financial-ax?utm_campaign
Inhibrx Announces Preliminary Data From The Phase 1 Trial Of Inbrx-109 For The Treatment Of Ewing Sarcoma
Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase 1
$1.5M Bet On Domo? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.
Why NIO Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Axcella Health Inc. (NASDAQ: AXLA) shares climbed 196% to $0.3335 after the company announced it was granted a patent for long COVID fatigue treatment.
PDD Holdings, UP Fintech Holding, Big Lots And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Tuesday. Here are some big stocks recording gains in today’s session.
iCoreConnect Inc. (NASDAQ: ICCT) shares jumped 70.4% to $2.7089 after dipping 20% on Monday.
Inhibrx Announces $200M Private Placement Financing; In The PIPE, Co Is Selling An Aggregate Of 3,621,314 Shares Of Its Common Stock At A Price Of $19.35 Per Share
Inhibrx, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today